
|Articles|March 22, 2004
Antipsychotics, obesity, diabetes: Breaking the lock
Second-generation antipsychotics (SGAs), while clinically better than their earlier counterparts, have been associated with dramatic weight gain, diabetes and an atherogenic lipid profile.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Hormone Replacement Therapy May Lower Dementia Risk in Postmenopausal Women
3
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
4
AI, Automation Are Transforming Pharmacies into Proactive Care Hubs
5







































